abrdn Life Sciences Investors (NYSE:HQL) Short Interest Up 339.8% in July

abrdn Life Sciences Investors (NYSE:HQL) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 62,733 shares, an increase of 339.8% from the June 30th total of 14,265 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 144,503 shares, the days-to-cover ratio is currently 0.4 days.

Hedge Funds Weigh In On abrdn Life Sciences Investors

Large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its holdings in abrdn Life Sciences Investors by 57.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 362,535 shares of the company’s stock worth $5,898,000 after acquiring an additional 132,098 shares in the last quarter. LPL Financial LLC raised its position in abrdn Life Sciences Investors by 20.0% during the fourth quarter. LPL Financial LLC now owns 448,846 shares of the company’s stock worth $7,532,000 after acquiring an additional 74,787 shares during the period. Landscape Capital Management L.L.C. acquired a new position in abrdn Life Sciences Investors during the fourth quarter worth $1,158,000. Raymond James Financial Inc. lifted its holdings in abrdn Life Sciences Investors by 20.3% during the second quarter. Raymond James Financial Inc. now owns 375,960 shares of the company’s stock valued at $4,816,000 after purchasing an additional 63,429 shares in the last quarter. Finally, Formidable Asset Management LLC lifted its holdings in abrdn Life Sciences Investors by 63.3% during the fourth quarter. Formidable Asset Management LLC now owns 124,445 shares of the company’s stock valued at $1,930,000 after purchasing an additional 48,252 shares in the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Trading Up 0.3%

Shares of abrdn Life Sciences Investors stock traded up $0.06 during trading hours on Monday, reaching $19.31. The stock had a trading volume of 154,559 shares, compared to its average volume of 123,979. The stock’s 50 day moving average is $18.53 and its 200 day moving average is $17.55. abrdn Life Sciences Investors has a twelve month low of $13.01 and a twelve month high of $21.32.

abrdn Life Sciences Investors Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Thursday, May 21st were paid a $0.56 dividend. This represents a $2.24 annualized dividend and a dividend yield of 11.6%. The ex-dividend date was Thursday, May 21st.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.